BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20068224)

  • 21. Use of Sirolimus (Rapamycin) for Treatment of Cytopenias and Lymphoproliferation Linked to Autoimmune Lymphoproliferative Syndrome (ALPS). Two Case Reports.
    Cayrol J; Garrido Colino C
    J Pediatr Hematol Oncol; 2017 May; 39(4):e187-e190. PubMed ID: 28234735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Presentation and diagnosis of autoimmune lymphoproliferative syndrome (ALPS).
    Lambert MP
    Expert Rev Clin Immunol; 2021 Nov; 17(11):1163-1173. PubMed ID: 34503378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation.
    Neven B; Magerus-Chatinet A; Florkin B; Gobert D; Lambotte O; De Somer L; Lanzarotti N; Stolzenberg MC; Bader-Meunier B; Aladjidi N; Chantrain C; Bertrand Y; Jeziorski E; Leverger G; Michel G; Suarez F; Oksenhendler E; Hermine O; Blanche S; Picard C; Fischer A; Rieux-Laucat F
    Blood; 2011 Nov; 118(18):4798-807. PubMed ID: 21885602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defective FAS-Mediated Apoptosis and Immune Dysregulation in Gaucher Disease.
    Miano M; Madeo A; Cappelli E; Lanza F; Lanza T; Stroppiano M; Terranova P; Venè R; Bleesing JJH; Di Rocco M
    J Allergy Clin Immunol Pract; 2020; 8(10):3535-3542. PubMed ID: 32702516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop.
    Oliveira JB; Bleesing JJ; Dianzani U; Fleisher TA; Jaffe ES; Lenardo MJ; Rieux-Laucat F; Siegel RM; Su HC; Teachey DT; Rao VK
    Blood; 2010 Oct; 116(14):e35-40. PubMed ID: 20538792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.
    Aspinall AI; Pinto A; Auer IA; Bridges P; Luider J; Dimnik L; Patel KD; Jorgenson K; Woodman RC
    Blood Cells Mol Dis; 1999; 25(3-4):227-38. PubMed ID: 10575548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Advances in the knowledge and management of autoimmune lymphoproliferative syndrome].
    Garrido Colino C
    An Pediatr (Barc); 2014 Feb; 80(2):122.e1-7. PubMed ID: 24055319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.
    Dowdell KC; Niemela JE; Price S; Davis J; Hornung RL; Oliveira JB; Puck JM; Jaffe ES; Pittaluga S; Cohen JI; Fleisher TA; Rao VK
    Blood; 2010 Jun; 115(25):5164-9. PubMed ID: 20360470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies.
    Consonni F; Gambineri E; Favre C
    Ann Hematol; 2022 Mar; 101(3):469-484. PubMed ID: 35059842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunologic evaluation and genetic defects of apoptosis in patients with autoimmune lymphoproliferative syndrome (ALPS).
    Casamayor-Polo L; López-Nevado M; Paz-Artal E; Anel A; Rieux-Laucat F; Allende LM
    Crit Rev Clin Lab Sci; 2021 Jun; 58(4):253-274. PubMed ID: 33356695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A unique phenotype of longitudinal extensive transverse myelitis in autoimmune lymphoproliferative syndrome.
    Dekeyser C; Naesens L; Offner F; De Vriendt C; Schauwvlieghe A; Kerre T; Laureys G
    J Neuroimmunol; 2022 Jun; 367():577866. PubMed ID: 35453041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tubulointerstitial nephritis in a patient with probable autoimmune lymphoproliferative syndrome.
    Glerup M; Herlin T; Rittig S; Grønbæk K; Hokland M; Hasle H
    J Pediatr Hematol Oncol; 2013 Jul; 35(5):e187-9. PubMed ID: 23588339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoimmune Lymphoproliferative Syndrome: An Overview.
    Matson DR; Yang DT
    Arch Pathol Lab Med; 2020 Feb; 144(2):245-251. PubMed ID: 30958694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS).
    Teachey DT; Obzut DA; Axsom K; Choi JK; Goldsmith KC; Hall J; Hulitt J; Manno CS; Maris JM; Rhodin N; Sullivan KE; Brown VI; Grupp SA
    Blood; 2006 Sep; 108(6):1965-71. PubMed ID: 16757690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children.
    George LA; Teachey DT
    Paediatr Drugs; 2016 Aug; 18(4):261-72. PubMed ID: 27139496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Underlying Inborn Errors of Immunity in Patients With Evans Syndrome and Multilineage Cytopenias: A Single-Centre Analysis.
    Miano M; Guardo D; Grossi A; Palmisani E; Fioredda F; Terranova P; Cappelli E; Lupia M; Traverso M; Dell'Orso G; Corsolini F; Beccaria A; Lanciotti M; Ceccherini I; Dufour C
    Front Immunol; 2022; 13():869033. PubMed ID: 35655776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-FDG PET Imaging Features of Patients With Autoimmune Lymphoproliferative Syndrome.
    Carrasquillo JA; Chen CC; Price S; Whatley M; Avila NA; Pittaluga S; Jaffe ES; Rao VK
    Clin Nucl Med; 2019 Dec; 44(12):949-955. PubMed ID: 31689275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The challenge of early diagnosis of autoimmune lymphoproliferative syndrome in children with suspected autoinflammatory/autoimmune disorders.
    Oliveira Mendonça L; Matucci-Cerinic C; Terranova P; Casabona F; Bovis F; Caorsi R; Fioredda F; Palmisani E; Grossi A; Guardo D; Bustaffa M; Volpi S; Ceccherini I; Ravelli A; Dufour C; Miano M; Gattorno M
    Rheumatology (Oxford); 2022 Feb; 61(2):696-704. PubMed ID: 33909886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Familial splenomegaly as a first clinical sign of autoimmune lymphoproliferative syndrome].
    Bilbao Aburto A; Arana Aguirre N; García Martínez JM; Astigarraga Aguirre I; Allende LM
    An Pediatr (Barc); 2010 Apr; 72(4):278-81. PubMed ID: 20227933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.
    Ruiz-García R; Mora S; Lozano-Sánchez G; Martínez-Lostao L; Paz-Artal E; Ruiz-Contreras J; Anel A; González-Granado LI; Moreno-Pérez D; Allende LM
    Pediatr Res; 2015 Dec; 78(6):603-8. PubMed ID: 26334989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.